Aprea Therapeutics, Inc. current report, 17 April 2023

Vollständiges Dokument

Aprea Therapeutics, Inc. Form 8-K Summary

Business context and reporting period

Aprea Therapeutics, Inc. filed a Current Report on Form 8-K dated April 17, 2023, reporting a change in its independent registered public accounting firm. The report was signed on April 18, 2023. The filing concerns the audit of the year ending December 31, 2023, and references prior-year audits for the years ended December 31, 2022 and 2021.

Key financial metrics

This filing does not provide revenue, profit or loss, cash flow, margins, debt, liquidity, or other operating or financial metrics.

Material changes versus the prior comparable period

  • Ernst & Young LLP was dismissed as the Company’s independent registered public accounting firm on April 17, 2023.
  • EisnerAmper LLP was engaged on the same date to audit the Company’s financial statements for the year ending December 31, 2023.
  • The Audit Committee approved both the dismissal and the appointment.

Audit matters, outlook, and risks

  • EY’s reports on the 2022 and 2021 financial statements contained no adverse opinion, disclaimer of opinion, or qualification or modification relating to uncertainty, audit scope, or accounting principles.
  • The Company reported no disagreements with EY regarding accounting principles or practices, financial statement disclosure, or audit scope or procedures during 2022, 2021, or through April 17, 2023.
  • The Company reported no “reportable events” as defined under applicable SEC rules.
  • The filing states that neither the Company nor anyone acting on its behalf consulted EisnerAmper on specified accounting, auditing, financial reporting, disagreement, or reportable-event matters during the relevant periods.
  • The filing provides no management guidance, operating outlook, contingencies, or unusual financial items.

Important facts for investors to verify

  • Review Exhibit 16.1, EY’s letter to the SEC, for EY’s confirmation or comments regarding the Company’s disclosures.
  • Confirm EisnerAmper’s appointment and its role as auditor for the year ending December 31, 2023.
  • Review subsequent periodic filings for any effect of the auditor transition on financial reporting, internal controls, audit timing, or auditor’s opinions.
  • Obtain the Company’s periodic financial statements separately, as this Form 8-K contains no financial performance or liquidity data.